BE CAR7 T / Great Ormond Street Hospital for Children - LARVOL DELTA

Combinational "Off-the-Shelf' CAR T Cells: A Unified Front Against AML Heterogeneity (ASGCT 2025) - "We generated 'universal', TCRαβ depleted BE-CAR7, BE-CAR33 and BE-CARCLL-1 CAR T cells and evaluated their application against highly heterogeneous and aggressive AML...Pre-manufactured and ready to use allogeneic combinations should enable timely interventions against AML where disease can otherwise evolve and progress rapidly. Disease Focus of Abstract:Cancer Hematologic"

CAR T-Cell Therapy • Heterogeneity • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Glomerulonephritis • Graft versus Host Disease • Immunology • B2M • CD33 • CD52 • CD7 • CD70

Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Trial completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD7

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. (PubMed, N Engl J Med) - "The interim results of this phase 1 study support further investigation of base-edited T cells for patients with relapsed leukemia and indicate the anticipated risks of immunotherapy-related complications. (Funded by the Medical Research Council and others; ISRCTN number, ISRCTN15323014.)."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • CD52 • CD7

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal" CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL (ASH 2022) - "Eligible patients receive lymphodepletion with fludarabine (150 mg/sqm), cyclophosphamide (120 mg/kg) and alemtuzumab (1 mg/kg), followed by infusion of 0.2-2.0x106 BE-CAR7 T cells (maximum 5x104/kg TCRαβ T cells). This Phase 1 study aims to treat 10 children in the UK. Conclusion The study has demonstrated the feasibility of manufacturing "off-the-shelf" GMP-compliant base edited CAR7 T cells and is investigating their safety and efficacy against paediatric r/r T-ALL."

Clinical • IO biomarker • P1 data • Bone Marrow Transplantation • Gene Therapies • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • Transplantation • CD52 • CD7

Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML (ASH 2022) - "Lentiviral transduction and multiplexed base editing to remove TCR, CD52 and the shared AML/T lineage antigen CD7, enabled the generation of universal donor CAR T cells for combinational use. This data demonstrates robust activity of BE-CAR33 alone and in combination with BE-CAR7 against human CD7+CD33+AML in mice and highlights the importance of strategies that ensure complete targeting of leukemic populations."

CAR T-Cell Therapy • IO biomarker • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD2 • CD33 • CD52 • CD7 • HAVCR2 • KIT • LAG3 • PD-1 • PD-L1 • PTPRC

Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust

New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD7